Cut through the noise.
Trade on the signal.
A weekly synthesis of institutional-grade financial reports and market mechanics.
No spam. Unsubscribe anytime.
Report Archive, Page 12
12 of 155 reportsRego Payment Architectures has A Weak Product, Recently Added Debt And Significant Dilution – 25c 1-Year Price Target
White Diamond Research exposes Rego Payment Architectures (RPMT) with a 75% downside risk, highlighting Mazoola's failed product, mounting $20M debt, minimal revenue, and potential stock dilution in the competitive fi...
Sell Lucid – We Believe Buyout Rumor is FAKE NEWS – Came Right After Lock-up Expiration
Fuzzy Panda Research exposes Lucid Group (LCID) stock manipulation through false Saudi PIF buyout rumor, revealing negative margins, poor delivery rates, and potential market deception in electric vehicle sector
Know Labs Is An Obvious Medical Device Scam, We’re Calling: “Theranos’ Retarded Cousin”
White Diamond Research exposes Know Labs (KNW) as a potential medical device scam, revealing zero revenue, unproven glucose monitoring technology, massive share dilution, and lack of scientific validation in devastati...
Fisker – Undisclosed Bank Guarantees Show the Cash is Pledged; Fisker’s History of Lies Revealed
Fisker Inc. exposed: EV maker faces critical financial challenges, alleged deception by CEO Henrik Fisker, hidden bank guarantees, and potential regulatory risks in electric vehicle production and startup governance
Part 2: New Red Flags Emerge From Veru’s Phase 3 Covid Trial, Suggesting An FDA Rejection Is Likely
White Diamond Research exposes critical flaws in Veru's COVID-19 drug trial, revealing data integrity issues, methodological problems, and potential FDA rejection risks for sabizabulin treatment
Part 1: New Red Flags Emerge From Veru’s Phase 3 Covid Trial, Suggesting An FDA Rejection Is Likely
Veru's Sabizabulin COVID-19 drug faces potential FDA rejection due to critical Phase 3 trial design flaws, small sample size, patient selection issues, and questionable mortality data suggesting ineffective treatment
Short Alphatec (Nasdaq: ATEC)
Bonitas Research exposes Alphatec Holdings (ATEC) alleged revenue inflation scheme, undisclosed FDA recalls, suspicious related-party distributors, insider selling, and financial irregularities threatening investor co...
Short Gogoro (Nasdaq: GGR)
Gogoro's electric scooter sales plummet 20% in Q2 2022, market share erodes as KYMCO challenges battery-swapping dominance, with declining registrations, compressed margins, and poor app ratings threatening growth
EVGO – A Broken “ESG” Company Connected to Jeffrey Epstein
EVGO stock analysis reveals 25.5% charger failure rate, -381% margins, Jeffrey Epstein connections, and massive overvaluation. Short-sellers expose critical EV charging infrastructure risks and corporate governance pr...
A2Z Smart Technologies: Used To Be Called Inrob Tech (A Pump And Dump Scam), Management Has A Shady Past, and Related Party Transactions – 50c Price Target
Exposing A2Z Smart Technologies (AZ) stock fraud: White Diamond Research reveals pump-and-dump scheme, questionable leadership, minimal revenue, and projected 85% stock price decline to $0.50 per share
Short MP Materials (NYSE: MP)
MP Materials NYSE stock faces serious allegations of transfer pricing manipulation, insider selling, and questionable rare earth mining economics at Mountain Pass California facility, raising significant investor conc...
ELMS – EV Pretender – Passing Off Chinese Imports as “Made in the USA”; Booking Fake Revenue of Fully Returnable Products?
ELMS EV Scandal: Imported Chinese Electric Vehicles Fraudulently Marketed as Made in USA, Facing Revenue Recognition Issues and Potential Insolvency Within 5 Months